Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 15Terminated 3Active not recruiting 2Unknown 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Lymphoid 1CNS 1

Conditions

Sezary Syndrome 1Neuroblastoma 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NIH × Interleukin-12 Subunit p35 × Clear all
NCT01307618 2016-10-24

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 8 charts
Dermatologic

Melanoma

NCT00054405 2013-04-09

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNS

Neuroblastoma

NCT00052377 2013-01-16

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡